Revenue
2024
2025
Alamar Biosciences, Inc. (ALMR)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Revenue | $74.2M | $25.1M |
| Gross profit | $41.7M | $8.6M |
| Research & development | $37.5M | $39.2M |
| Operating income | −$31.3M | −$49.6M |
| EBITDAderived | −$27.5M | −$46.4M |
| Net income | −$29.2M | −$47.1M |
| Diluted EPSper diluted share | -$2.58 | -$4.60 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 20, 2026Form 4 | Naclerio NicholasDirector | BuyCommon Stock · indirect | 235.3K | $17.00 | $4.00M | 507.1K |
| Apr 20, 2026Form 4 | Illumina Innovation Fund II GP, L.L.C. +4TenPercentOwner | BuyCommon Stock · indirect | 235.3K | $17.00 | $4.00M | 507.1K |